

## **Sancuso® Newly Recommended in Guideline for Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies**

TOKYO, Japan, June 27, 2019 - Solasia Pharma K.K. (TOKYO:4597, Headquarters:Tokyo, Japan, President & CEO:Yoshihiro Arai, hereinafter "Solasia"), a specialty pharmaceutical company based in Asia, today officially announced that the granisetron transdermal patch "Sancuso®" (SP-01, product name in China: 善可舒®, hereinafter "Sancuso®"), has been newly recommended in the "Guidelines of prevention and treatment of nausea and vomiting caused by antitumor therapies" (hereinafter referred as "Guideline") issued by CSCO (Chinese Society of Clinical Oncology). CSCO is the largest and most prestigious medical society in the Cancer field in China.

Sancuso® had been previously recommended by the CRPC (Committee of Rehabilitation and Palliative Care of China Anti-cancer Association) which is a subsidiary association of CSCO. This time, the first new Guideline by CSCO recommended Sancuso® as standard of care for CINV (Chemotherapy induced nausea and vomiting) treatment.

Professor Qin Shukui, deputy director of CSCO, Guideline team leader and Director of Cancer Center of PLA General Hospital of Eastern Theater Command, stated, "In this Guideline, we emphasize the importance of the whole process management of nausea and vomiting throughout cancer treatment, which is to prevent severe nausea and vomiting during chemotherapy and properly managing delayed nausea and vomiting which occurs a few days after chemotherapy. In China, intravenous antiemetic was conventionally used which has short onset of action, but recently some experts point out that the rapid change of drug concentration can be harmful to peripheral vessels, and also repetitive injection being inconvenient. Sancuso® is designed to gradually release Granisetron up to 7 days, and is currently the only transdermal Granisetron patch in the world. By administering 1 patch, Sancuso® can control both acute and delayed nausea and vomiting which are induced by highly and moderately emetogenic chemotherapy, providing a non-invasive and tolerable treatment option to cancer patients. This could especially benefit patients receiving multi-day chemotherapy and patients who have difficulty in oral intake of drug."

Professor Chen Yingxia, main writer of Guideline and Ward Chief of Cancer Center of PLA General Hospital of Eastern Theater Command, commented, "The benefit of Sancuso® is that it can meet the needs of different patients without oral or injection administration route. Physicians need to suggest treatment options considering patient's condition, economic status and ease of use, etc. Sancuso® will provide a new option with more convenience for whole process management of chemotherapy induced nausea and vomiting."

###

### **About Sancuso®**

Sancuso® is the Granisetron transdermal system used for the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy regimens. Each 52cm<sup>2</sup> patch contains 34.3mg of Granisetron and releases 3.1mg of Granisetron every 24 hours for up to 7 days. Granisetron transdermal system is a persistently effective noninvasive drug delivery system with a proven safety profile. To date, Sancuso® has been launched in over 20 countries and regions including the United States, UK, Germany, the Netherlands, and Denmark. In 2014, a clinic pharmacology study as well as a random and double-blind clinical study versus oral Granisetron was completed in China. It was approved by the China National Medical Products Administration (NMPA) in July 2018 and launched in China.

### **About Solasia**

Solasia is an Asia-based pharmaceutical company dedicated to developing and selling innovative cancer treatment supportive drugs for local markets. As to benefit patients in China, the company is focused on creating a cancer treatment system in Asia, by developing innovative cancer drugs, introducing and getting commercial development licenses for great products from leading pharmaceutical and biotech companies in Japan, Europe and U.S.A, and other Asian countries. Solasia actively responds to the needs of patients and healthcare professionals and works hard to improve patient's life and meet the key unmet needs in oncology. For more information about the company, please visit [www.solasia.co.jp/en/](http://www.solasia.co.jp/en/)

## NEWS RELEASE

*Solasia*

(Contact)

**Solasia Pharma K.K.**

Rie Toyoda, Public Relations and Investor Relations

Tel: +81 3 5843 8049 (Japan)

[info@solasia.co.jp](mailto:info@solasia.co.jp)

**Solasia Medical Information Consulting (Shanghai) Co. Ltd. (苏爱康医药信息咨询 (上海) 有限公司)**

Aili Xu, Director, Marketing Department

Tel: +86 21 5068 6185 (China)

[info1@solasia.com.cn](mailto:info1@solasia.com.cn)